RxDoctor Payments DataLook up a doctor →

Kelsey Martin, APRN

Acute Care · Nashville, TNNPI 1619478559

Payments from drug & device makers

$41,836in general payments, 2019–2025

Across 411 payments — averaging $101.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$33K
  • AstraZeneca$1K
  • Stemline Therapeutics Inc.$932
  • Regeneron Healthcare Solutions, Inc.$863
  • Daiichi Sankyo Inc.$719
  • Novartis$535
  • plus $4K from 53 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead96$33,282
AstraZeneca(2 entities)26$1,118
Stemline Therapeutics Inc.4$932
Regeneron Healthcare Solutions, Inc.31$863
Daiichi Sankyo Inc.22$719
Novartis20$535
Merck14$400
Eisai Inc.14$302
Johnson & Johnson15$267
E.r. Squibb & Sons, L.L.C.11$204
Pfizer10$188
Bayer10$169
Tersera Therapeutics LLC9$163
Lilly USA, LLC7$151
Exelixis Inc.6$131
AVEO Pharmaceuticals, Inc.3$122
Sanofi4$121
Genentech USA, Inc.7$114
Bristol Myers Squibb6$114
EMD Serono, Inc.5$100
Array Biopharma Inc5$99
Servier Pharmaceuticals LLC5$98
Astellas Pharma US Inc5$96
Seagen Inc.4$92
Incyte Corporation4$91
G1 Therapeutics, Inc.4$91
Jazz Pharmaceuticals Inc.3$79
Mirati Therapeutics, Inc.4$76
Springworks Therapeutics, Inc.3$73
Genmab U.S., Inc.3$71
Rigel Pharmaceuticals, Inc.4$67
Organon3$63
AbbVie3$51
Puma Biotechnology, Inc.3$51
Deciphera Pharmaceuticals Inc.2$50
Takeda Pharmaceuticals U.S.A., Inc.2$49
Beigene USA, Inc.3$49
Tempus AI, Inc2$47
Progenics Pharmaceuticals, Inc.2$45
Amgen3$44
Blueprint Medicines Corporation1$42
Beone Medicines USA, Inc.2$41
Novocure Inc.2$35
Sun Pharmaceutical Industries Inc.2$34
Caris MPI, Inc.2$34
Coherus Oncology, Inc.2$30
Pharmacyclics LLC, An Abbvie Company1$25
Verity Pharmaceuticals Inc.1$21
Iovance Biotherapeutics, Inc.1$21
Celltrion USA Inc.1$20
CTI Biopharma Corp.1$19
Agios Pharmaceuticals, Inc.1$19
GSK1$19
Pharmaessentia USA Corporation1$18
Boehringer Ingelheim1$17
Spectrum Pharmaceuticals Inc.1$17
Kyowa Kirin, Inc.1$16
Sobi, Inc1$16
Pharmacosmos Therapeutics Inc.1$14

How this compares

$41,836 in reported general payments places this provider in the 95th percentile of 738 acute care providers in Tennessee.

See all acute care providers in Tennessee →

Medicare billing

Part B allowed, 2024
$1,520
Medicare patients
12
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in Nashville

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →